Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

July 24, 2022 by Alan Khadavi

Viaskin Peanut Patch Safety Results

The Viaskin Peanut Patch is still being studied in clinical trials. Current treatment options for peanut allergy are limited. Peanut allergy is common with increasing prevalence reported. Peanut allergy only resolves in approximately 20% of children, otherwise it remains lifelong.

Currently the only FDA approved treatment for peanut allergy is Palforzia.

Palforzia (formerly AR101) and peanut allergy

We have written previously about the Viaskin Peanut Patch being developed by DBV Technologies, VP250. It works by epicutaneous immunotherapy by inducing immune properties of the skin delivering microgram amounts of peanut. Viaskin Peanut Patch (DBV712) 250 micrograms (VP250) has undergone safety and efficacy trials in phase 2 and 3 studies.

In a recent study published titled “Safety of Epicutaneous Immunotherapy in Peanut Allergic Children: REALISE Randomized Clinical Trial Results”, researchers examined the safety in children, using a study design approximating potential real-world use.

REAL LIfe Use and Safety of EPIT (REALISE), is a 6 month study of children aged 4-11 with a diagnosis of peanut allergy receiving daily treatment of the Viaskin Peanut Patch (VP250) up to 36 months.

The results were as follows:

  • 396 children with peanut allergy were enrolled and they randomized to receive 3:1 of VP250 of the Viaskin Peanut Patch
  • All participants receiving VP250 and 83.8% receiving placebo reported at least 1 episode of local skin reaction, with frequency decreasing over time.
  • Only 1.4% of participants receiving the Viaskin Peanut Patch discontinued because of adverse events.
  • Epinephrine was administered in 2.4% of participants receiving VP250, none involved severe anaphylaxis.

The Peanut Patch seems to be well tolerated in peanut allergic children. This study had no efficacy assessment and more results will be needed in the future if this gets FDA approval. But peanut allergy is an ongoing challenge as accidental ingestion remains problematic and it is a significant source of stress for children and their families.

Having options available for peanut desensitization would be welcome for doctors and their patients besides oral immunotherapy (OIT) which can have a higher rate of reactions.

Risk for Peanut Allergy Severity

Ara h 2 is the most important peanut allergen

Flying with Peanut Allergy, is it safe?

AR101 a Potential Peanut Allergy Cure

How to introduce peanuts in infants

How much peanut will cause an allergic reaction?

Maternal Peanut Consumption while Breast-Feeding

 

 

Filed Under: Blog, Food allergy

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

September 22, 2023

How to treat Eosinophilic Esophagitis (EoE)

eosinophilic esophagitis treatment

September 14, 2023

Barley Allergy: Diagnosis and Management

barley allergy

September 11, 2023

Can the Covid Vaccine cause Hives?

covid vaccine and hives

August 30, 2023

Hops Allergy: Etiology, Presentation & Management

hops allergy

August 29, 2023

Dupixent for COPD, a new indication

dupixent for copd

August 10, 2023

Is Singulair Safe to Use? A study of Montelukast

Is Singulair safe?

July 24, 2023

Why am I so Itchy? Management of Chronic Itch

chronic itch

July 19, 2023

Potato Allergy: Can I be allergic to Potatoes?

potato allergy

July 18, 2023

Blueberry Allergy, can I be allergic to it?

blueberry allergy

June 30, 2023

Coffee Allergy: Can you be allergic to it?

coffee allergy

Read More Posts...

Follow Us…

© 2023 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page